Investing.com - Genmab AS reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Genmab AS announced earnings per share of $0.2086 on revenue of $357.76M. Analysts polled by Investing.com anticipated EPS of $0.1273 on revenue of $338.06M.
Genmab AS shares are up 12% from the beginning of the year and are trading at $42.34 , down-from-52-week-high.They are under-performing the STOXX 600 which is up 21.23% from the start of the year.
Genmab AS follows other major Healthcare sector earnings this month
Genmab AS's report follows an earnings beat by UnitedHealth on Thursday, October 14, 2021, who reported EPS of $4.52 on revenue of $72.34B, compared to forecasts EPS of $4.42 on revenue of $71.38B.
Eli Lilly had missed expectations on Tuesday, October 26, 2021 with third quarter EPS of $1.94 on revenue of $6.77B, compared to forecast for EPS of $1.96 on revenue of $6.64B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar